[HTML][HTML] Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
M Puccetti, A Schoubben, S Giovagnoli… - International Journal of …, 2023 - mdpi.com
As an appealing alternative to treat and prevent diseases ranging from cancer to COVID-19,
mRNA has demonstrated significant clinical effects. Nanotechnology facilitates the …
mRNA has demonstrated significant clinical effects. Nanotechnology facilitates the …
The ADME characteristics of siRNA therapeutics and the opportunity to predict disposition in pregnant women.
O Amaeze, N Isoherranen, S Shum - Drug Metabolism and Disposition, 2024 - ASPET
Small interfering RNA (siRNA) therapeutics represent an emerging class of
pharmacotherapy with the potential to address previously hard-to-treat diseases. Currently …
pharmacotherapy with the potential to address previously hard-to-treat diseases. Currently …
Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis
A von Mässenhausen, MN Schlecht, K Beer… - Science …, 2024 - science.org
Small interfering RNAs (siRNAs) are widely used in biomedical research and in clinical
trials. Here, we demonstrate that siRNA treatment is commonly associated with significant …
trials. Here, we demonstrate that siRNA treatment is commonly associated with significant …
Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and small-molecule drugs in tumor treatment
Y Dang, Y Feng, X Chen, C He, S Wei, D Liu, J Qi… - Chinese Chemical …, 2024 - Elsevier
The combination of nucleic acid and small-molecule drugs in tumor treatment holds
significant promise; however, the precise delivery and controlled release of drugs within the …
significant promise; however, the precise delivery and controlled release of drugs within the …
Peptide-Modified Cyclodextrin-Based Nanosystem for Co-Delivery of Celastrol and siPD-L1 to Tumors
D Wang, T Zhang, Y Hu, Y Luo, Y Li… - ACS Applied Nano …, 2024 - ACS Publications
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with high
immunogenicity. In this study, we developed a peptide-modified cyclodextrin-based …
immunogenicity. In this study, we developed a peptide-modified cyclodextrin-based …
Controlled siRNA Release of Nanopolyplex for Effective Targeted Anticancer Therapy in Animal Model
J Jia, J Yang, L Qian, B Zhou, X Tang… - International Journal …, 2024 - Taylor & Francis
Introduction Spatiotemporally controlled release of siRNA for anti-tumor therapy poses
significant challenges. Near-infrared (NIR) light, known for its exceptional tissue penetration …
significant challenges. Near-infrared (NIR) light, known for its exceptional tissue penetration …
PEG-modified nano liposomes co-deliver Apigenin and RAGE-siRNA to protect myocardial ischemia injury
C Liu, X Zhang, H Yang, M Zhao, Y Liu, R Zhao… - International Journal of …, 2024 - Elsevier
Ischemic heart disease (IHD) is a cardiac disorder in which myocardial damage occurs as a
result of myocardial ischemia and hypoxia. Evidence suggests that oxidative stress and …
result of myocardial ischemia and hypoxia. Evidence suggests that oxidative stress and …
Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
Y Yuan, L Li, J Earp, L Ma, VA Bhattaram… - The Journal of …, 2024 - Wiley Online Library
The application of model‐informed drug development (MIDD) has revolutionized drug
development and regulatory decision making, transforming the process into one that is more …
development and regulatory decision making, transforming the process into one that is more …
Types of RNA therapeutics.
P Goleij, M Babamohamadi, A Rezaee… - Progress in Molecular …, 2024 - europepmc.org
RNA therapy is one of the new treatments using small RNA molecules to target and regulate
gene expression. It involves the application of synthetic or modified RNA molecules to inhibit …
gene expression. It involves the application of synthetic or modified RNA molecules to inhibit …